

Our Ref: 15
JANUARY 2024

Re: Your request made under the Freedom of Information Act 2000

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]- 17
- Adalimumab [Humira] - 23
- Adalimumab Biosimilars - 394
- Apremilast [Otezla] - 1
- Baricitinib [Olumiant] - 55
- Bimekizumab [Bimzelx] - 0
- Certolizumab [Cimzia] - 13
- Etanercept [Enbrel] - 27
- Etanercept Biosimilars - 164
- Filgotinib [Jyseleca] - 65
- Golimumab [Simponi] - 40
- Guselkumab [Tremfya] - 4
- Infliximab [Remicade] - 7
- Infliximab Biosimilars - 12
- Ixekizumab [Taltz] - 10
- Risankizumab [Skyrizi] - 0
- Rituximab [MabThera] - 0
- Rituximab Biosimilars - 24
- Sarilumab [Kevzara] - 4
- Secukinumab [Cosentyx] - 55
- Tocilizumab [Ro Actemra] - 41
- Tocilizumab Biosimilars - 0
- Tofacitinib [Xeljanz] - 5
- Upadacitinib [Rinvoq] - 24
- Ustekinumab [Stelara] - 4

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs.

- Adalimumab [Humira]
- Adalimumab Biosimilars
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Golimumab [Simponi]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Secukinumab [Cosentyx]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- **Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**

Our Ref: 15
JANUARY 2024